Whistleblowers Raise Concerns Over Alzheimer's Drug Trials
The whistleblowers claim that phase two trial data for the drug raised alarm bells. They expressed skepticism that the drug's pharmacology makes sense based on the available data. The scientists' concerns focus on difficulties in interpreting the basic science results. A whistleblower claims that data patterns in Alzheimer's drug trials are not random accidents but show a coherent pattern that changes data interpretation.
Topics
Developing
- 862d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 862d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 862d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 862d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
WNYC 93.9 FM
“They had produced some data from their phase two trials that raised alarm bells for these whistleblowers. Who were the whistleblowers? They were a pair of scientists, a cardiologist and a neuroscientist.”
WNYC 93.9 FM
“And then also to show that these are not random things, that these are not accidents or slips, but that there is a coherent pattern to it that changes the interpretation of the data.”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade